The focus of our research is to understand the global genetic determinants of cancer development and therapeutic response. We primarily utilize data generated by next-generation sequencing technologies to study genomic mutations, copy number alterations, structural variations, and transcriptome changes, which together provide a molecular profile of individual tumors.
We collaborate closely with clinical investigators and researchers to integrate molecular and clinical information so as to identify molecular determinants of clinical phenotypes, thereby allowing more precise stratification of patient populations and targeting of cancer therapeutics.
William Lee, PhD
Research Focus
Computational biologist William Lee focuses on the application of high-throughput sequencing technologies for cancer biomarker discovery and diagnostics.Publications
- Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, Ha C, Johnson S, Kennemer MI, Mohan S, Nazarenko I, Watanabe C, Sparks AB, Shames DS, Gentleman R, de Sauvage FJ, Stern H, Pandita A, Ballinger DG, Drmanac R, Modrusan Z, Seshagiri S, Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010 May 27;465(7297):473-7. doi: 10.1038/nature09004.
- Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, Chan TA. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013 Jul;45(7):791-8. doi: 10.1038/ng.2643. Epub 2013 May 19.
